Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: COVID

In brief

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

Key facts

Study ID
NCT04447469
Run by
Kiniksa Pharmaceuticals International, plc
People needed
814
Starts
2020-07-28
Expected to finish
2022-01-14
Last updated by the study team
2025-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.